Light Sciences Corporation comprises two companies developing Light InfusionTechnology ™ (Litx ™) for treatment of significant unmet medical needs incardiovascular and eye disease. Light Sciences has also continued to seek new applications for Litx on other important disease targets.
Litx ™ is a combination product consisting of a proprietary photoreactive agent (LS11) activated by proprietary non-coherent light infusion devices. The goal of Litx™ is less poorly formed blood vessels that support the development of abnormaltissues in the proliferative diseases.
Targeting age-related macular degeneration and other diseases affecting the backof the eye.
Targeting of atherosclerosis, including peripheral arterial disease and vulnerableplaque.
Light Sciences New Technology Group (NTG) is a seed-stage R & D organizationchartered to incubate innovation and technology in a wide range of applications including healthcare products and groundbreaking use of LED technology.
Light Sciences Oncology was previously a wholly owned subsidiary of Light Sciences Corporation. It completed a $ 35,000,000 financing in October 2005 andis now an independent company targeting primary liver cancer, colorectal livermetastases and other solid tumors.